28 September 2022 - CRISPR Therapeutics today announced that the US FDA granted regenerative medicine advanced therapy designation to CTX130, ...
31 August 2022 - New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting ...
25 August 2022 - First TIL therapy BLA submission initiated with U.S. FDA. ...
17 August 2022 - Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing. ...
17 August 2022 - Today, the US FDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of ...
15 August 2022 - Last year, the FDA issued a rare public statement to inform the ALS community that a ...
15 August 2022 - Haematopoietic stem cell gene therapy has proven to be an effective treatment for several primary immunodeficiencies, and ...
1 August 2022 - PDUFA target action date is 30 January 2023. ...
26 July 2022 - Expanding new medical treatments requires pushing — and sometimes breaking — the boundaries of what currently ...
24 June 2022 - In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30 year ...
2 June 2022 - Omidubicel has orphan drug designation and breakthrough therapy designation. ...
25 May 2022 - The approval of tisagenlecleucel and axicabtagene ciloleucel in 2017 marked a milestone in the development of oncology ...
27 May 2022 - 68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response ...
17 May 2022 - The US FDA's top biologics regulator said the use of a “playbook” or platform approach ...
3 May 2022 - GPH101 is an investigational next-generation gene-edited therapy designed to potentially provide a one time cure for ...